-
公开(公告)号：US10155740B2
公开(公告)日：2018-12-18
申请号：US15560723
申请日：2016-11-24
IPC分类号： C07D401/04 , A61P35/00
摘要： The present invention relates to novel solid crystal forms of Pomalidomide named Form B, Form M, Pomalidomide:Gentisic acid co-crystal and their preparation. Advantageously, these solid forms are used in pharmaceutical compositions for the treatment and the prevention of multiple myeloma, of inflammatory diseases, of autoimmune diseases, of immune diseases, of myelodysplastic syndrome, of myeloproliferative disorders, of anemia, of scleroderma, amyloidosis or of other diseases associated with unwanted angiogenesis.
-
公开(公告)号：US11267791B2
公开(公告)日：2022-03-08
申请号：US17263642
申请日：2019-07-25
发明人： Nicolas Tesson , Jordi De Mier Vinue , Paolo Stabile , Pierluigi Padovan , Matteo De Poli , Angelo Restelli
IPC分类号： C07D231/46
摘要： Object of the present invention is a highly stable crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D1, having the highest thermodynamically stability with excellent non-hygroscopicity, and particularly well suitable for pharmaceutical purposes, with related process.
-
公开(公告)号：US11214547B2
公开(公告)日：2022-01-04
申请号：US17263636
申请日：2019-07-25
发明人： Nicolas Tesson , Jordi De Mier Vinue , Paolo Stabile , Pierluigi Padovan , Matteo De Poli , Angelo Restelli
IPC分类号： C07D231/46
摘要： Object of the present invention is a better crystalline form of Eltrombopag (ETP) monoethanolamine salt, named Form D, stable, suitable for pharmaceutical purposes, and with the highest solubility in water and excellent non-hygroscopicity, then the related process and intermediates thereof.
-
公开(公告)号：US09822063B2
公开(公告)日：2017-11-21
申请号：US15115133
申请日：2015-10-26
IPC分类号： C07C217/54 , C07C59/265 , C07C217/18 , C07C51/41 , C07C53/10 , C07C213/08
CPC分类号： C07C217/54 , C07B2200/13 , C07C51/412 , C07C53/10 , C07C59/265 , C07C213/08 , C07C217/18
摘要： The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.
-
公开(公告)号：US09738607B2
公开(公告)日：2017-08-22
申请号：US15215782
申请日：2016-07-21
发明人： Nicolas Tesson , Carmen Jiménez , Llorenç Rafecas , Marta Pontini
IPC分类号： C07C309/30 , C07C31/08 , A61K31/44 , A61K47/48 , C07D213/81
CPC分类号： C07D213/81 , A61K31/44 , A61K47/54 , C07C31/08 , C07C309/30
摘要： The present invention refers to an improved process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III.
-
6.发明申请SCALABLE PROCESS FOR THE PREPARATION OF SORAFENIB TOSYLATE ETHANOL SOLVATE AND SORAFENIB TOSYLATE FORM III 有权磺酰苯甲酸乙酯溶解剂和磺酰基甲酸酯形式III的制备方法公开(公告)号：US20160376236A1
公开(公告)日：2016-12-29
申请号：US15215782
申请日：2016-07-21
发明人： Nicolas Tesson , Carmen Jiménez , Llorenç Rafecas , Marta Pontini
IPC分类号： C07D213/81 , A61K47/48 , A61K31/44 , C07C309/30 , C07C31/08
CPC分类号： C07D213/81 , A61K31/44 , A61K47/54 , C07C31/08 , C07C309/30
摘要： The present invention refers to an improved process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III.
摘要翻译： 本发明涉及一种制备索拉非尼甲苯磺酸乙酯溶剂化物和索拉非尼甲苯磺酸盐形式III的改进方法。
-
公开(公告)号：US08815862B2
公开(公告)日：2014-08-26
申请号：US13691881
申请日：2012-12-03
发明人： Clark Ferrari , Andrea Castellin , Marco Galvagni , Nicolas Tesson , Jordi De Mier , Llorenç Rafecas
IPC分类号： C07D241/42 , C07D239/69 , C07D241/12 , C07D239/42
CPC分类号： C07D241/42 , C07D239/42 , C07D239/69 , C07D241/12
摘要： Methods for the preparation of Rosuvastatin by co-crystals of Rosuvastatin or intermediates are provided. Also provided are co-crystals, pharmaceutical compositions which include such co-crystals and methods for treating conditions associated with hypercholesterolemia by administering such compositions.
摘要翻译： 提供了通过罗苏伐他汀或中间体的共晶制备罗苏伐他汀的方法。 还提供了共晶体，包括这种共晶体的药物组合物和通过施用这样的组合物来治疗与高胆固醇血症相关的病症的方法。
-
公开(公告)号：US20130143890A1
公开(公告)日：2013-06-06
申请号：US13691881
申请日：2012-12-03
发明人： Clark Ferrari , Andrea Castellin , Marco Galvagni , Nicolas Tesson , Jordi De Mier , Llorenç Rafecas
IPC分类号： C07D241/42 , C07D241/12 , C07D239/69
CPC分类号： C07D241/42 , C07D239/42 , C07D239/69 , C07D241/12
摘要： Methods for the preparation of Rosuvastatin by co-crystals of Rosuvastatin or intermediates are provided. Also provided are co-crystals, pharmaceutical compositions which include such co-crystals and methods for treating conditions associated with hypercholesterolemia by administering such compositions.
摘要翻译： 提供了通过罗苏伐他汀或中间体的共晶制备罗苏伐他汀的方法。 还提供了共晶体，包括这种共晶体的药物组合物和通过施用这样的组合物来治疗与高胆固醇血症相关的病症的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.018 秒)
